Please login to the form below

Not currently logged in
Email:
Password:

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

MSD Merck Sharp Dohme Jessica FineMSD has appointed Jessica Fine as executive director, external affairs for its UK operations.

She will join MSD, which operates as Merck & Co in the US, in April when she will replace Kate Tillett who retires early next year.

Fine will move to the pharma firm from Lexington Communications, on whose senior management team she sat and where she served as head of Lexington Health.

While there she led the health arm of the business and delivered strategic counsel to a range of organisations and providers across the healthcare sector. She was also highly commended in the Publicis Life Brands Resolute Award for Emerging Leader in Healthcare Communications at last year's Communiqué Awards.

Mike Nally, managing director of MSD in the UK, said: “Jessica has a wealth of experience and expertise in healthcare communications and I'm looking forward welcoming Jessica and the leadership qualities that I know she will bring to this role.”

In her new role heading up MSD's external affairs team in the UK, Fine will cover public affairs, policy and therapy area communications, external and internal communications.

17th December 2015

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics